These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6549167)

  • 1. Tolerance and pharmacokinetics of A515U, an acyclovir analogue, in healthy volunteers.
    Whiteman PD; Bye A; Fowle AS; Jeal S; Land G; Posner J
    Eur J Clin Pharmacol; 1984; 27(4):471-5. PubMed ID: 6549167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A515U: a prodrug of acyclovir with increased oral bioavailability.
    Rees PJ; Selby P; Prentice HG; Whiteman PD; Grant DM
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():215-22. PubMed ID: 3793661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino (hydroxyethoxymethyl) purine: a new well-absorbed prodrug of acyclovir.
    Selby P; Powles RL; Blake S; Stolle K; Mbidde EK; McElwain TJ; Hickmott E; Whiteman PD
    Lancet; 1984 Dec; 2(8417-8418):1428-30. PubMed ID: 6151046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir.
    Krenitsky TA; Hall WW; de Miranda P; Beauchamp LM; Schaeffer HJ; Whiteman PD
    Proc Natl Acad Sci U S A; 1984 May; 81(10):3209-13. PubMed ID: 6587347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tolerance of desciclovir, a prodrug of acyclovir, in healthy human volunteers.
    Petty BG; Whitley RJ; Liao S; Krasny HC; Rocco LE; Davis LG; Lietman PS
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1317-22. PubMed ID: 3674844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical pharmacology of acyclovir and its prodrugs.
    Brigden D; Whiteman P
    Scand J Infect Dis Suppl; 1985; 47():33-9. PubMed ID: 3868024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The disposition of 6-deoxyacyclovir, a xanthine oxidase-activated prodrug of acyclovir, in the isolated perfused rat liver.
    Jones DB; Rustgi VK; Kornhauser DM; Woods A; Quinn R; Hoofnagle JH; Jones EA
    Hepatology; 1987; 7(2):345-8. PubMed ID: 3557315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection.
    Weller IV; Tedder RS; Karayiannis P; Thomas HC; Fiddian AP
    J Hepatol; 1986; 3 Suppl 2():S119-22. PubMed ID: 3598153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir.
    Good SS; Krasny HC; Elion GB; de Miranda P
    J Pharmacol Exp Ther; 1983 Dec; 227(3):644-51. PubMed ID: 6655561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
    Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.
    de Miranda P; Burnette TC
    Drug Metab Dispos; 1994; 22(1):55-9. PubMed ID: 8149890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat.
    Burnette TC; de Miranda P
    Drug Metab Dispos; 1994; 22(1):60-4. PubMed ID: 8149891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers.
    Pue MA; Pratt SK; Fairless AJ; Fowles S; Laroche J; Georgiou P; Prince W
    J Antimicrob Chemother; 1994 Jan; 33(1):119-27. PubMed ID: 8157552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of desciclovir, a prodrug of acyclovir, in humans after multiple oral dosing.
    Krasny HC; Petty BG
    J Clin Pharmacol; 1987 Jan; 27(1):74-7. PubMed ID: 3680558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of oral acyclovir (Zovirax) in the eye.
    Hung SO; Patterson A; Rees PJ
    Br J Ophthalmol; 1984 Mar; 68(3):192-5. PubMed ID: 6696872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
    Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
    Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.
    Simon MW; Fish DN; Deeter RG
    Drugs R D; 2002; 3(6):365-73. PubMed ID: 12516939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on acyclovir: oral therapy for herpesvirus infections.
    True BL; Carter BL
    Clin Pharm; 1984; 3(6):607-13. PubMed ID: 6096075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses.
    Tsujimura K; Yamada M; Nagata S; Yamanaka T; Nemoto M; Kondo T; Kurosawa M; Matsumura T
    J Vet Med Sci; 2010 Mar; 72(3):357-61. PubMed ID: 19959884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerance of acyclovir, a new anti-herpesvirus agent, in humans.
    Laskin OL; Longstreth JA; Saral R; de Miranda P; Keeney R; Lietman PS
    Antimicrob Agents Chemother; 1982 Mar; 21(3):393-8. PubMed ID: 7103443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.